Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Thondikulam Subramanian

Neurology Trinity, FL Medical Doctor

NPI 1326085416 CMS profile 286373

1226 Tuscany Dr, Trinity, FL 34655

Open in the dashboard

General payments

$5,678

275 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Thondikulam Subramanian of Trinity, FL is reported in the CMS Open Payments database as having received $5,678 across 275 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $564 30
2022 General $1,314 62
2021 General $1,098 72
2020 General $777 44
2019 General $1,926 67

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thondikulam Subramanian
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Thondikulam Subramanian were reported at $0. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Thondikulam Subramanian Neurology median Middle half National median
2019 $1,926 $474 $118–$2,177 $163
2020 $777 $367 $82–$2,309 $114
2021 $1,098 $438 $104–$2,547 $132
2022 $1,314 $442 $103–$2,388 $149
2023 $564 $464 $119–$2,312 $160
2024 $0 $468 $119–$2,323 $164
2025 $0 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. AbbVie, Inc. $659 33 payments
  2. Novartis Pharmaceuticals Corporation $536 26 payments
  3. Teva Pharmaceuticals USA, Inc. $396 21 payments
  4. EMD Serono, Inc. $390 14 payments
  5. Biogen, Inc. $371 21 payments
  6. Eisai Inc. $355 16 payments
  7. Amgen Inc. $269 10 payments
  8. UCB, Inc. $259 17 payments
  9. Alexion Pharmaceuticals, Inc. $197 5 payments
  10. CSL Behring $176 9 payments
  11. Other $2,069 103 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $5,603 273 payments
  2. Education $62 1 payment
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $13 1 payment
Products named General payments · program years 2019–2023
  1. Fycompa $355 16 payments
  2. NURTEC ODT $315 21 payments
  3. AIMOVIG $297 12 payments
  4. MAYZENT $293 11 payments
  5. Mavenclad $273 7 payments
  6. DUOPA $269 10 payments
  7. AUSTEDO $239 10 payments
  8. VUMERITY $236 13 payments
  9. Briviact $221 14 payments
  10. ZEPOSIA $217 7 payments
  11. Other $3,200 172 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

19

Median for Neurology: 833

Drug cost

$568

Median for Neurology: $202,670

Branded share of claims

100%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Carbidopa-Levodopa Carbidopa/Levodopa Brand 19 $568

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$56,619

Medicare's payments for the services billed

Medicare patients

167

Average age 75

Services billed

632

88 women, 79 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 69%
Ischemic heart disease 60%
Depression 53%
Diabetes 51%
Chronic kidney disease 51%
Heart failure 44%
COPD 38%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

275 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record